Table 2.
The clinic study about the concentration of SFRPs in patients with metabolism disease.
| Genotype | Study population (number) | Concentration of SFRPs | References |
|---|---|---|---|
| SFRP4 | Obese Patients Study | Obese: 137.8±33.6 ng/mL; Lean: 64.1±23.8 ng/mL. | (61) |
| Lean (n=8); obese (n=12). | |||
| SFRP4 | Obese Patients Study | PW: 1086±167 pg/mL; LF: 1307±181pg/mL; LGI: 1346 ±211 pg/mL; VLC: 1220 ±205 pg/mL. | (60) |
| LF (n=21); LGI (n=21); VLC (n=21). | |||
| SFRP4 | Diabetic Study | NGT: 95.46 ± 20.13 ng/mL; IGT: 141.64 ± 40.46 ng/mL; T2DM: 184.38 ± 61.34 ng/mL. | (113) |
| NGT (n=42); IGT(n=52); T2DM (n =56). | |||
| SFRP4 | Diabetic Study | Control: 8.8 ± 3.0 ng/mL; CO-T1D: 16.9 ± 4.5 ng/mL; T2D: 37.1 ± 26.7 ng/mL; LADA: 15.6 ± 6.2 ng/mL; T1D: 24.6 ± 17.9 ng/mL. | (114) |
| Control (n=30); T1D (n=46); T2D (n=55); CO-T1D (n=30); LADA (n=37). | |||
| SFRP4 | Diabetic Study | NGT: 0.170 (0.12–0.45) ng/mL; IGT: 0.183 (0.13–0.70) ng/mL; T2DM: 0.282 (0.11-2.51) ng/mL. | (115) |
| NGT (n=36); IGT (n=34); T2DM (n=82). | |||
| SFRP4 | Pregnant with Diabetic Study | Control: 5.59 ± 3.32 ng/mL; GDM: 4.05 ± 2.15 ng/mL. | (116) |
| Control (n=41); GDM (n=35). | |||
| SFRP4 | Women with PCOS | Control: 5.87 ± 1.91 ng/mL; PCOS: 3.72 ± 1.29 ng/mL. | (117) |
| Control (n=80); PCOS (n=80). | |||
| SFRP5 | Diabetic Study | NGT-NW :13.12±3.62 ng/mL; NGT-OB: 9.46±2.70 ng/mL; T2DM-NW: 10.12±3.45 ng/mL; T2DM-OB: 6.70±2.34 ng/mL; Men: 9.71±3.86 ng/mL; Women: 10.01±3.82 ng/mL. | (121) |
| NGT-NW (n=46); NGT-OB (n=43); T2DM-NW (n=42); T2DM-OB (n=45). | |||
| SFRP5 | Diabetic Study | T2DM: 9.4±9.0 ng/mL; non-diabetics: 7.4±10.9 ng/mL; Male: 9.8±10.7 ng/mL; Female:7.3±8.2 ng/mL. | (122) |
| T2DM (n=82), non-diabetics (n=42). | |||
| SFRP5 | Diabetic Study | Controls: 22.98±12.36 ng/mL; T2DM: 14.14±11.91 ng/mL; LADA: 14.82±11.27 ng/mL. | (124) |
| Controls (n=40); T2DM (n=58); LADA (n=22). | |||
| SFPR5 | MetS Study | Control subjects: 61.6±23.2 µg/L; MetS patients: 49.1±17.2 µg/L. | (125) |
| Control (n=194); MetS patients (n=90). | |||
| SFRP5 | Diabetic Study | Controls: 10.4 (6.7-16.6) ng/mL; T2DM: 15.6 (9-24.5) ng/mL; prediabetic subjects: 9.8(5-14.2) ng/mL. | (127) |
| Controls (n=70); T2DM (n=70); prediabetic subjects (n=70). |
CO-T1D, controls, age matched for patients with type 1 diabetes; GDM, gestational diabetes mellitus; IGT, impaired glucose tolerance; LADA, latent autoimmune diabetes of the adult; LF, low fat; LGI, low glycemic index; MetS, metabolic syndrome; NGT, normal glucose tolerance; NGT-NW, normal glucose tolerance-Normal weight; NGT-OB, normal glucose tolerance-obese; PCOS, polycystic ovary syndrome; PW, pre-weight; T1D, type 1 diabetes; T2, type 2 diabetes; T2DM, type 2 diabetes mellitus; T2DM-NW, type 2 diabetes mellitus-normal weight; T2DM-OB, type 2 diabetes mellitus-obese; VLC, very low carbohydrate.